This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.
Lymphoma, Non-Hodgkin, Hodgkin Lymphoma
This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
-
Research Site, Miami, Florida, United States, 33136
Research Site, Atlanta, Georgia, United States, 30322
Research Site, Boston, Massachusetts, United States, 02215
Research Site, Philadelphia, Pennsylvania, United States, 19104
Research Site, Houston, Texas, United States, 77030
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
15 Years to
ALL
No
AstraZeneca,
2026-05-08